Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice

Biochemical Pharmacology

Volumn 59, Issue 7, 2000, Pages 831-837

  Loadman, Paul M ^a   Phillips, Roger M ^a   Lim, Lissa E ^a   Bibby, Mike C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Bioreductive; DT diaphorase; EO9; Metabolism; Pharmacokinetics; RH1

Indexed keywords

2,5 DIAZIRIDINYL 3 HYDROXYMETHYL 6 METHYL 1,4 BENZOQUINONE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; AZIRIDINYLBENZOQUINONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY METABOLISM; LIVER METABOLISM; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HUMANS; INDOLEQUINONES; INDOLES; KINETICS; LUNG NEOPLASMS; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM TRANSPLANTATION;

EID: 0033981669     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00391-3     Document Type: Article

References (29)

1. Brown J.M., Giaccia A.J. The unique physiology of solid tumors Opportunities (and problems) for cancer therapy . Cancer Res. 58:1998;1408-1416.
2. Ernster L. DT-diaphorase; A historical review. Chem Scripta. 27A:1987;1-13.
3. Schlager J.J., Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue Effects of cigarette smoking and alcohol . Int J Cancer. 45:1990;403-409.
4. Malkinson A.M., Siegel D., Forrest G.L., Gazdar A.F., Oie H.K., Chan D.C., Bunn P.A., Mabry M., Dykes D.J., Harrison S.D., Ross D. Elevated DT diaphorase activity and messenger Rna content in human non-small cell lung carcinoma Relationship to the response of lung tumor xenografts to mitomycin C1 . Cancer Res. 52:1992;4752-4757.
5. Phillips R.M. Human DT-diaphorase as a candidate for enzyme-directed bioreductive drug development. Drugs of the Future. 21:1996;1247-1256.
6. Fisher G.R., Donis J., Gutierrez P.L. Reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells. II. Enhancement of the alkylating activity of AZQ by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) . Biochem Pharmacol. 44:1992;1625-1635.
7. Cummings J., Spanswick V.J., Tomasz M., Smyth J.F. Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem Pharmacol. 56:1998;405-414.
8. Winski S.L., Hargreaves R.H., Butler J., Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent . Clin Cancer Res. 4:1998;3083-3088.
9. Walton M.I., Smith P.J., Workman P. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Commun. 3:1991;199-206.
10. Hendriks H.R., Pizao P.E., Berger D.P., Kooistra K.L., Bibby M.C., Boven E., Dreef-van der Meulen H.C., Henrar R.E., Fiebig H.H., Double J.A., Hornstra H.W., Pinedo H.M., Workman P., Schwartsmann G. EO9 A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models . Eur J Cancer. 29A:1993;897-906.
11. Robertson N., Haigh A., Adams G.E., Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro DT-diaphorase activity and hypoxia . Eur J Cancer. 30A:1994;1013-1019.
12. Pavlidis N., Hanauske A.R., Gamucci T., Smyth J., Lehnert M., te Velde A., Lan J., Verweij J. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer A study of the EORTC early clinical studies group (ECSG) . Ann Oncol. 7:1996;529-531.
13. Dirix L.Y., Tonnesen F., Cassidy J., Epelbaum R., Huinink W.W., Pavlidis N., Sorio R., Gamucci T., Wolff I., te Velde A., Lan J., Verweij J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. Eur J Cancer. 32A:1996;2019-2022.
14. Verweij J., Aamdal S., Schellens J., Koier I., Lund B. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. Oncol Res. 6:1994;519-523.
15. Phillips R.M., Loadman P.M., Cronin B.C. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer. 77:1998;2112-2119.
16. Workman P., Binger M., Kooistra K.L. Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys. 22:1992;713-716.
17. Bibby M.C., Sleigh N.R., Loadman P.M., Double J.A. Potentiation of EO9 anti-tumour activity by hydralazine. Eur J Cancer. 29A:1993;1033-1035.
18. Segura-Aguilar J., Cremades A., Llombart-Bosch A., Monsalve E., Ernster L., Romero F. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. Carcinogenesis. 15:1994;1631-1636.
19. Phillips R.M., Loadman P.M., Jarret C.M. Species-dependent differences in the metabolism of idoloquinones by whole blood. Br J Cancer. 75:(Suppl 1):1997;20.
20. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., Embleton J., Newell D., Raymond R., Stables J., Stephens T., Wallace J. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 77:1998;1-10.
21. Phillips R.M. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase. Biochem Pharmacol. 52:1996;1711-1718.
22. Phillips R.M., Hulbert P.B., Bibby M.C., Sleigh N.R., Double J.A. In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity. Br J Cancer. 65:1992;359-364.
23. Bibby M.C., Loadman P.M., al-Ghabban A.F., Double J.A. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br J Cancer. 65:1992;347-350.
24. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
25. Phillips R.M. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA) Implications for bioreductive drug development . Biochem Pharmacol. 58:1999;303-310.
26. McKeage M.J., Kestell P., Denny W.A., Baguley B.C. Plasma pharamcokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol. 28:1991;409-413.
27. Henderson P.F. Statistical analysis of enzyme kinetic data. Eisenthal R., Danson M.J. Enzyme Assays A Practical Approach . 1993;277-316 IRL Press, Oxford University Press, Oxford.
28. Khan P., Abbas S., Hargreaves R.H., Caffrey R., Megram V., McGown A. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumour agent RH1 in human and mouse plasma. J Chromatogr B Biomed Sci App. 729:1999;287-295.
29. 5 reductase in human tumour cells . Br J Cancer. 74:1996;1188-1193.